(UroToday.com) In a stand-alone session at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, titled Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes, Dr. Alicia Morgans covered data on the rapidly evolving landscape of systemic therapy for patients with advanced prostate cancer including, in particular, data from recent trials examining modern therapeutic options in non-metastatic castration-resistant prostate cancer (nmCRPC) and in metastatic hormone-sensitive prostate cancer (mHSPC).